Huoman J, 2021 Sweden
To investigate epigenome-wide DNA methylation patterns from a sub group of children from an on-going allergy prevention trial using pre- and postnatal combined L. reuteri and ω-3 fatty acid treatment.
Sub-group of children in on-going R, DB, PC trial.
1) L. reuteri + ω-3 PUFA: n = 18
2) probiotics + placebo: n = 16,
3) ω-3 + placebo: n = 15,
4) double placebo: n = 14
Prenatal L. reuteri and/or ω-3 fatty acid treatment resulted in hypermethylation and affected immune- and allergy-related pathways in neonatal T helper cells. The results show potential synergistic effects between the interventions.
Forsberg A, 2020
Sweden
To investigate how maternal peripheral immunity is affected by pregnancy, and by probiotic and ω-3 fatty acid supplementation.
R, DB, PC From gesta tional week 20 until birth
1) L. reuteri + ω-3 PUFA: 22
2) ω-3 PUFA + placebo: 21
3) placebo + ω-3 PUFA: 22
4) placebo capsules + pla cebo oil: 23 (L. reuteri: 1×109 CFU, 20 droplets × 2 daily; ω-3 PUFA: 3840 mg)
Probiotic supplementation to the mother during the second half of pregnancy resulted in immunomodulatory effects among activated and resting Treg cells. Furthermore, several systemic immune modifying effects of pregnancy were observed.
Forsberg A, 2020
(Substudy of Abrahamsson, 2007) Sweden
To assess the effects of pre-and postnatal L. reuteri supplementa tion on DNA methylation in relation to immune maturation and allergy development.
R, DB, PC Women were supplemented from gestational week 36, children were supplemen ted for the first year of life
L. reuteri: 95 (1×108 CFU) PMaternal L. reuteri supplementation during pregnancy alters DNA methylation patterns in CD4+ T cells towards enhanced immune activation at birth, which may affect immune maturation and allergy development.lacebo: 93
Maternal L. reuteri supplementation during pregnancy alters DNA methylation patterns in CD4+ T cells towards enhanced immune activation at birth, which may affect immune maturation and allergy development.
Abrahamsson T, 2007
Sweden
Prevention of atopic eczema in infants 0–2 years old.
R, DB, PC 12 months + Substudy at 24 months
L. reuteri: 95 (1×108 CFU) Placebo: 93
• Significantly fewer in the L. reuteri group with IgE-associa ted eczema at 2 years of age
• Skin prick test reactivity to allergens was less common in the L. reuteri vs. the placebo group, significantly so for infants with mothers with allergies
• The overall incidence of eczema was the same in the two groups at 2 years of age.
Abrahamsson T, 2011
(Substudy of Abrahamsson
Prevention of allergy/atopic eczema in infants 0-2 years old.
R, DB, PC 12 months + follow-up at 24 months
L. reuteri: 95 (1×108 CFU) Placebo: 93
Infants with faecal L. reuteri the first week of life had a less allergy-prone chemokine profile in their blood at 6 months of age.
Abrahamsson TR, 2013
(Follow-up of Abrahamsson 2007) Sweden
In a study on prevention of allergy in newborns, L. reuteri ATCC 55730 reduced the incidence of IgE-asso ciated allergic disease in infancy. This treatment might therefore also reduce the risk of asthma and allergic rhino conjunctivitis in school age (at the age of 7), which this follow-up study set out to investigate. It also evalua ted whether this supplementation was associated with any long-term side effects.
Original study: R, DB, PC
L. reuteri: 94 (1×108 CFU) Placebo: 90 In the 2007 trial 232 infants were randomized and 188 completed
For the allergic disease outcomes there were no differen ces between groups:
• The prevalence of asthma was 15% in the L. reuteri vs. 16% in placebo group
• Allergic rhino conjunctivitis: 27% vs. 20%
• Eczema: 21% vs. 19% • Skin prick test reactivity: 29% vs. 26%
Ceratto S, 2014 (abstract, follow- up of Savino 2010) Italy
If probiotic treatment for infant colic may prevent atopic diseases (cow’s milk allergy and atopic dermatitis), asthma and migraine at the age of five, and effects on growth.
Original study: R, DB, PC
L. reuteri: 25 (1×108 CFU) Placebo: 23
• The prevalence of atopic disorders was significantly lower in the L. reuteri group compared to placebo, with an odds ratio of 0.16.
• Asthma was absent in both groups and there was one case of migraine, in the placebo group.
• Growth was equal in the two groups, measured as BMIZ-score.